Review Article | Published:

Translating p53 into the clinic

Nature Reviews Clinical Oncology volume 8, pages 2537 (2011) | Download Citation

  • A Correction to this article was published on 30 September 2011

This article has been updated

Abstract

Mutations in the TP53 gene are a feature of 50% of all reported cancer cases. In the other 50% of cases, the TP53 gene itself is not mutated but the p53 pathway is often partially inactivated. Cancer therapies that target specific mutant genes are proving to be highly active and trials assessing agents that exploit the p53 system are ongoing. Many trials are aimed at stratifying patients on the basis of TP53 status. In another approach, TP53 is delivered as a gene therapy; this is the only currently approved p53-based treatment. The p53 protein is overexpressed in many cancers and p53-based vaccines are undergoing trials. Processed cell-surface p53 is being exploited as a target for protein–drug conjugates, and small-molecule drugs that inhibit the activity of MDM2, the E3 ligase that regulates p53 levels, have been developed by several companies. The first MDM2 inhibitors are being trialed in both hematologic and solid malignancies. Finally, the first agent found to restore the active function of mutant TP53 has just entered the clinic. Here we discuss the basis of these trials and the future of p53-based therapy.

Key points

  • 151 trials exploiting the p53 pathway have been conducted

  • TP53 gene therapy (Gendicine) using an adenovirus vector was approved by the Chinese State Food and Drug Administration (SFDA) in 2003

  • Small-molecule inhibitors of the p53–MDM2 interaction are efficacious in animal models and are in clinical trials for the treatment of solid and hematologic malignancies

  • Cyclotherapy—using a p53 activator to protect normal tissue from cytotoxic drugs and increase the therapeutic index in the treatment of TP53-mutant cancer—was effective in animal studies

Access optionsAccess options

Rent or Buy article

Get time limited or full article access on ReadCube.

from$8.99

All prices are NET prices.

Change history

  • 23 August 2011

    In the version of this article initially published online a software error resulted in several incorrect citations and two missing references: National Cancer Institute http://seer.cancer.gov/ (2010) and Met, O. et al. Breast Cancer Res. Treat. 125, 395–406 (2011). The errors have been corrected for the HTML and PDF versions of the article.

References

  1. 1.

    , , & Targeted cancer therapies in the twenty-first century: lessons from imatinib. Clin. Pharmacol. Ther. 87, 543–552 (2010).

  2. 2.

    Promoting apoptosis as a strategy for cancer drug discovery. Nat. Rev. Cancer 5, 876–885 (2005).

  3. 3.

    et al. ABT-263: a potent and orally bioavailable Bcl-2 family inhibitor. Cancer Res. 68, 3421–3428 (2008).

  4. 4.

    & Targeted therapy for cancer using PARP inhibitors. Curr. Opin. Pharmacol. 8, 363–369 (2008).

  5. 5.

    , , & Discovery and development of bevacizumab, an anti-VEGF antibody for treating cancer. Nat. Rev. Drug Discov. 3, 391–400 (2004).

  6. 6.

    National Cancer Institute. Surveilance Epidemiology and End Results , (2010).

  7. 7.

    , , , & Awakening guardian angels: drugging the p53 pathway. Nat. Rev. Cancer 9, 862–873 (2009).

  8. 8.

    , & p53-based cancer therapy. Cold Spring Harb. Perspect. Biol. 2, a001222 (2010).

  9. 9.

    et al. Biomarkers predict p53 gene therapy efficacy in recurrent squamous cell carcinoma of the head and neck. Clin. Cancer Res. 15, 7719–7725 (2009).

  10. 10.

    et al. Retrovirus-mediated wild-type p53 gene transfer to tumors of patients with lung cancer. Nat. Med. 2, 985–991 (1996).

  11. 11.

    & Why did p53 gene therapy fail in ovarian cancer? Lancet Oncol. 4, 415–422 (2003).

  12. 12.

    et al. p53 therapy in a patient with Li-Fraumeni syndrome. Mol. Cancer Ther. 6, 1478–1482 (2007).

  13. 13.

    & An update on gene therapy in China. Curr. Opin. Mol. Ther. 11, 547–553 (2009).

  14. 14.

    , , , & Novel recombinant adenoviral vector that targets the interleukin-13 receptor alpha2 chain permits effective gene transfer to malignant glioma. Hum. Gene Ther. 18, 118–129 (2007).

  15. 15.

    et al. An adenovirus mutant that replicates selectively in p53-deficient human tumor cells. Science 274, 373–376 (1996).

  16. 16.

    et al. A controlled trial of intratumoral ONYX-015, a selectively-replicating adenovirus, in combination with cisplatin and 5-fluorouracil in patients with recurrent head and neck cancer. Nat. Med. 6, 879–885 (2000).

  17. 17.

    et al. Late viral RNA export, rather than p53 inactivation, determines ONYX-015 tumor selectivity. Cancer Cell 6, 611–623 (2004).

  18. 18.

    , , , & Anti-HER2 vaccines: new prospects for breast cancer therapy. Cancer Immunol. Immunother. 59, 1295–1312 (2010).

  19. 19.

    , & Cancer immunotherapy: co-stimulatory agonists and co-inhibitory antagonists. Clin. Exp. Immunol. 157, 9–19 (2009).

  20. 20.

    et al. Efficacy and safety of ipilimumab monotherapy in patients with pretreated advanced melanoma: a multicenter single-arm phase II study. Ann. Oncol. 21, 1712–1717 (2010).

  21. 21.

    et al. Improved survival with ipilimumab in patients with metastatic melanoma. N. Engl. J. Med. 363, 711–723 (2010).

  22. 22.

    et al. Single-institution experience with ipilimumab in advanced melanoma patients in the compassionate use setting: lymphocyte count after 2 doses correlates with survival. Cancer 116, 1767–1775 (2010).

  23. 23.

    p53-based immunotherapy of cancer. Crit. Rev. Immunol. 18, 29–35 (1998).

  24. 24.

    et al. Frequencies of tetramer+ T cells specific for the wild-type sequence p53264–272 peptide in the circulation of patients with head and neck cancer. Cancer Res. 62, 3521–3529 (2002).

  25. 25.

    , , & Serum p53 antibodies in patients with lung cancer: correlation with clinicopathologic features and smoking. Lung Cancer 39, 297–301 (2003).

  26. 26.

    et al. Absence of p53 autoantibodies in a significant proportion of breast cancer patients. Br. J. Cancer 71, 1253–1256 (1995).

  27. 27.

    , , & High immunogenic potential of p53 mRNA-transfected dendritic cells in patients with primary breast cancer. Breast Cancer Res. Treat. 125, 395–406 (2011).

  28. 28.

    et al. Induction of p53-specific immunity by a p53 synthetic long peptide vaccine in patients treated for metastatic colorectal cancer. Clin. Cancer Res. 15, 1086–1095 (2009).

  29. 29.

    et al. Long lasting p53-specific T cell memory responses in the absence of anti-p53 antibodies in patients with resected primary colorectal cancer. Eur. J. Immunol. 31, 146–155 (2001).

  30. 30.

    et al. Magnitude and polarization of P53-specific T-helper immunity in connection to leukocyte infiltration of colorectal tumors. Int. J. Cancer 107, 425–433 (2003).

  31. 31.

    , , , & Immunologic aspect of ovarian cancer and p53 as tumor antigen. J. Transl. Med. 3, 34 (2005).

  32. 32.

    , , , & INGN-225: a dendritic cell-based p53 vaccine (Ad.p53-DC) in small cell lung cancer: observed association between immune response and enhanced chemotherapy effect. Expert Opin. Biol. Ther. 10, 983–991 (2010).

  33. 33.

    , , & Mdm2 promotes the rapid degradation of p53. Nature 387, 296–299 (1997).

  34. 34.

    & Targeting the ubiquitin-proteasome system to activate wild-type p53 for cancer therapy. Semin. Cancer Biol. 20, 29–39 (2010).

  35. 35.

    , & The p53 orchestra: Mdm2 and Mdmx set the tone. Trends Cell Biol. 20, 299–309 (2010).

  36. 36.

    et al. Structure of the MDM2/MDMX RING domain heterodimer reveals dimerization is required for their ubiquitylation in trans. Cell Death Differ. 15, 841–848 (2008).

  37. 37.

    et al. Mutual dependence of MDM2 and MDMX in their functional inactivation of p53. J. Biol. Chem. 277, 19251–19254 (2002).

  38. 38.

    et al. Cooperative signals governing ARF-mdm2 interaction and nucleolar localization of the complex. Mol. Cell Biol. 20, 2517–2528 (2000).

  39. 39.

    et al. The Ink4a tumor suppressor gene product, p19Arf, interacts with MDM2 and neutralizes MDM2's inhibition of p53. Cell 92, 713–723 (1998).

  40. 40.

    , , , & Nucleolar Arf sequesters Mdm2 and activates p53. Nat. Cell Biol. 1, 20–26 (1999).

  41. 41.

    , & MdmX binding to ARF affects Mdm2 protein stability and p53 transactivation. J. Biol. Chem. 276, 25336–25341 (2001).

  42. 42.

    et al. Twist is a potential oncogene that inhibits apoptosis. Genes Dev. 13, 2207–2217 (1999).

  43. 43.

    et al. Senescence bypass screen identifies TBX2, which represses Cdkn2a (p19(ARF)) and is amplified in a subset of human breast cancers. Nat. Genet. 26, 291–299 (2000).

  44. 44.

    et al. Bmi-1 regulation of INK4A-ARF is a downstream requirement for transformation of hematopoietic progenitors by E2a-Pbx1. Mol. Cell 12, 393–400 (2003).

  45. 45.

    et al. Ink4a and Arf differentially affect cell proliferation and neural stem cell self-renewal in Bmi1-deficient mice. Genes Dev. 19, 1438–1443 (2005).

  46. 46.

    , , , & Bmi-1 promotes neural stem cell self-renewal and neural development but not mouse growth and survival by repressing the p16Ink4a and p19Arf senescence pathways. Genes Dev. 19, 1432–1437 (2005).

  47. 47.

    & Mdm2-mediated ubiquitylation: p53 and beyond. Cell Death Differ. 17, 93–102 (2010).

  48. 48.

    & The INK4A/ARF locus and its two gene products. Curr. Opin. Genet. Dev. 9, 22–30 (1999).

  49. 49.

    et al. In vivo activation of the p53 pathway by small-molecule antagonists of MDM2. Science 303, 844–848 (2004).

  50. 50.

    et al. Design of a synthetic Mdm2-binding mini protein that activates the p53 response in vivo. Curr. Biol. 7, 860–869 (1997).

  51. 51.

    , & Small-molecule inhibitors of MDM2 as new anticancer therapeutics. Semin. Cancer Biol. 20, 10–18 (2010).

  52. 52.

    et al. MDM2 antagonists induce p53-dependent apoptosis in AML: implications for leukemia therapy. Blood 106, 3150–3159 (2005).

  53. 53.

    , , & The MDM2 inhibitor Nutlins as an innovative therapeutic tool for the treatment of haematological malignancies. Curr. Pharm. Des. 14, 2100–2110 (2008).

  54. 54.

    et al. JNJ-26481585, a novel “second-generation” oral histone deacetylase inhibitor, shows broad-spectrum preclinical antitumoral activity. Clin. Cancer Res. 15, 6841–6851 (2009).

  55. 55.

    et al. Temporal activation of p53 by a specific MDM2 inhibitor is selectively toxic to tumors and leads to complete tumor growth inhibition. Proc. Natl Acad. Sci. USA 105, 3933–3938 (2008).

  56. 56.

    et al. Small molecule RITA binds to p53, blocks p53-HDM-2 interaction and activates p53 function in tumors. Nat. Med. 10, 1321–1328 (2004).

  57. 57.

    et al. Ablation of key oncogenic pathways by RITA-reactivated p53 is required for efficient apoptosis. Cancer Cell 15, 441–453 (2009).

  58. 58.

    , , & MDM2 antagonist nutlin-3 is a potent inducer of apoptosis in pediatric acute lymphoblastic leukemia cells with wild-type p53 and overexpression of MDM2. Leukemia 22, 730–739 (2008).

  59. 59.

    et al. Functional integrity of the p53-mediated apoptotic pathway induced by the nongenotoxic agent nutlin-3 in B-cell chronic lymphocytic leukemia (B-CLL). Blood 107, 4122–4129 (2006).

  60. 60.

    et al. The oncogene DEK promotes leukemic cell survival and is downregulated by both Nutlin-3 and chlorambucil in B-chronic lymphocytic leukemic cells. Clin. Cancer Res. 16, 1824–1833 (2010).

  61. 61.

    et al. Nongenotoxic activation of the p53 pathway as a therapeutic strategy for multiple myeloma. Blood 106, 3609–3617 (2005).

  62. 62.

    , , & Rescue of embryonic lethality in Mdm2-deficient mice by absence of p53. Nature 378, 206–208 (1995).

  63. 63.

    , & Rescue of early embryonic lethality in mdm2-deficient mice by deletion of p53. Nature 378, 203–206 (1995).

  64. 64.

    , , , & Mdm2 is critically and continuously required to suppress lethal p53 activity in vivo. Cancer Cell 10, 501–514 (2006).

  65. 65.

    , , & Mdm2 targets the p53 transcription cofactor JMY for degradation. EMBO Rep. 8, 84–90 (2007).

  66. 66.

    , , , & Mdm2 induces mono-ubiquitination of FOXO4. PLoS ONE 3, e2819 (2008).

  67. 67.

    et al. ERK promotes tumorigenesis by inhibiting FOXO3a via MDM2-mediated degradation. Nat. Cell Biol. 10, 138–148 (2008).

  68. 68.

    et al. MDM2 acts downstream of p53 as an E3 ligase to promote FOXO ubiquitination and degradation. J. Biol. Chem. 284, 13987–14000 (2009).

  69. 69.

    et al. Induction of p53-dependent senescence by the MDM2 antagonist nutlin-3a in mouse cells of fibroblast origin. Cancer Res. 67, 7350–7357 (2007).

  70. 70.

    et al. MDM2 antagonist Nutlin-3 suppresses the proliferation and differentiation of human pre-osteoclasts through a p53-dependent pathway. J. Bone Miner. Res. 22, 1621–1630 (2007).

  71. 71.

    & p53 and metabolism. Nat. Rev. Cancer 9, 691–700 (2009).

  72. 72.

    et al. Simultaneous activation of p53 and inhibition of XIAP enhance the activation of apoptosis signaling pathways in AML. Blood 115, 306–314 (2010).

  73. 73.

    et al. Antitumor activity of the selective MDM2 antagonist nutlin-3 against chemoresistant neuroblastoma with wild-type p53. J. Natl Cancer Inst. 101, 1562–1574 (2009).

  74. 74.

    et al. Small-molecule MDM2 antagonists reveal aberrant p53 signaling in cancer: implications for therapy. Proc. Natl Acad. Sci. USA 103, 1888–1893 (2006).

  75. 75.

    et al. Reversal of P-glycoprotein-mediated multidrug resistance by the murine double minute 2 antagonist nutlin-3. Cancer Res. 69, 416–421 (2009).

  76. 76.

    , & Cyclin-dependent kinase inhibitors sensitize tumor cells to nutlin-induced apoptosis: a potent drug combination. Mol. Cancer Res. 5, 1133–1145 (2007).

  77. 77.

    , & (R)-roscovitine (CYC202, Seliciclib) sensitizes SH-SY5Y neuroblastoma cells to nutlin-3-induced apoptosis. Exp. Cell Res. 312, 2394–2400 (2006).

  78. 78.

    , , & Combination of nutlin-3 and VX-680 selectively targets p53 mutant cells with reversible effects on cells expressing wild-type p53. Cell Death Differ. 17, 1486–1500 (2010).

  79. 79.

    , , , & Concomitant inhibition of Mdm2-p53 interaction and Aurora kinases activates the p53-dependent postmitotic checkpoints and synergistically induces p53-mediated mitochondrial apoptosis along with reduced endoreduplication in acute myelogenous leukemia. Blood 112, 2886–2895 (2008).

  80. 80.

    et al. MDM2 antagonist nutlin-3 displays antiproliferative and proapoptotic activity in mantle cell lymphoma. Clin. Cancer Res. 15, 933–942 (2009).

  81. 81.

    et al. MDM2 antagonists activate p53 and synergize with genotoxic drugs in B-cell chronic lymphocytic leukemia cells. Blood 107, 4109–4114 (2006).

  82. 82.

    et al. Mdm2 inhibitor Nutlin-3a induces p53-mediated apoptosis by transcription-dependent and transcription-independent mechanisms and may overcome Atm-mediated resistance to fludarabine in chronic lymphocytic leukemia. Blood 108, 993–1000 (2006).

  83. 83.

    et al. Disruption of p73-MDM2 binding synergizes with gemcitabine to induce apoptosis in HuCCT1 cholangiocarcinoma cell line with p53 mutation. Tumour Biol. 31, 287–295 (2010).

  84. 84.

    , & Nutlin-3 radiosensitizes hypoxic prostate cancer cells independent of p53. Mol. Cancer Ther. 7, 993–999 (2008).

  85. 85.

    et al. Radiosensitization of lung cancer by nutlin, an inhibitor of murine double minute 2. Mol. Cancer Ther. 5, 411–417 (2006).

  86. 86.

    , , & TNF-related apoptosis-inducing ligand (TRAIL): a potential candidate for combined treatment of hematological malignancies. Curr. Pharm. Des. 10, 3673–3681 (2004).

  87. 87.

    et al. DNA binding cooperativity of p53 modulates the decision between cell-cycle arrest and apoptosis. Mol. Cell 38, 356–368 (2010).

  88. 88.

    , , , & NPM-ALK inhibits the p53 tumor suppressor pathway in an MDM2 and JNK-dependent manner. Blood 113, 5217–5227 (2009).

  89. 89.

    et al. Nutlin-3 up-regulates the expression of Notch1 in both myeloid and lymphoid leukemic cells, as part of a negative feedback antiapoptotic mechanism. Blood 113, 4300–4308 (2009).

  90. 90.

    , , & Survival signaling by Notch1: mammalian target of rapamycin (mTOR)-dependent inhibition of p53. Cancer Res. 66, 4715–4724 (2006).

  91. 91.

    , , , & Smac, a mitochondrial protein that promotes cytochrome c-dependent caspase activation by eliminating IAP inhibition. Cell 102, 33–42 (2000).

  92. 92.

    et al. Phase I/II trial of AEG35156 X-linked inhibitor of apoptosis protein antisense oligonucleotide combined with idarubicin and cytarabine in patients with relapsed or primary refractory acute myeloid leukemia. J. Clin. Oncol. 27, 4741–4746 (2009).

  93. 93.

    et al. A novel type of cellular senescence that can be enhanced in mouse models and human tumor xenografts to suppress prostate tumorigenesis. J. Clin. Invest. 120, 681–693 (2010).

  94. 94.

    et al. Senescence and tumour clearance is triggered by p53 restoration in murine liver carcinomas. Nature 445, 656–660 (2007).

  95. 95.

    et al. Activation of p53 by MDM2 antagonists can protect proliferating cells from mitotic inhibitors. Cancer Res. 65, 1918–1924 (2005).

  96. 96.

    & Nongenotoxic p53 activation protects cells against S-phase-specific chemotherapy. Cancer Res. 66, 10274–10280 (2006).

  97. 97.

    & Protection of p53 wild type cells from taxol by nutlin-3 in the combined lung cancer treatment. BMC Cancer 10, 57 (2010).

  98. 98.

    et al. Nutlin-3 protects kidney cells during cisplatin therapy by suppressing Bax/Bak activation. J. Biol. Chem. 282, 2636–2645 (2007).

  99. 99.

    et al. Structure-based design of spiro-oxindoles as potent, specific small-molecule inhibitors of the MDM2-p53 interaction. J. Med. Chem. 49, 3432–3435 (2006).

  100. 100.

    et al. Structure-based design of potent non-peptide MDM2 inhibitors. J. Am. Chem. Soc. 127, 10130–10131 (2005).

  101. 101.

    et al. Reactivation of p53 by a specific MDM2 antagonist (MI-43) leads to p21-mediated cell cycle arrest and selective cell death in colon cancer. Mol. Cancer Ther. 7, 1533–1542 (2008).

  102. 102.

    et al. An MDM2 antagonist (MI-319) restores p53 functions and increases the life span of orally treated follicular lymphoma bearing animals. Mol. Cancer 8, 115 (2009).

  103. 103.

    et al. MI-63: a novel small-molecule inhibitor targets MDM2 and induces apoptosis in embryonal and alveolar rhabdomyosarcoma cells with wild-type p53. Br. J. Cancer 101, 774–781 (2009).

  104. 104.

    et al. MDM2 inhibitor MI-319 in combination with cisplatin is an effective treatment for pancreatic cancer independent of p53 function. Eur. J. Cancer 46, 1122–1131 (2010).

  105. 105.

    , , , & A small molecule that disrupts Mdm2-p53 binding activates p53, induces apoptosis and sensitizes lung cancer cells to chemotherapy. Cancer Biol. Ther. 7, 845–852 (2008).

  106. 106.

    et al. Comprehensive biomarker and genomic analysis identifies p53 status as the major determinant of response to MDM2 inhibitors in chronic lymphocytic leukemia. Blood 111, 1584–1593 (2008).

  107. 107.

    et al. Multiple distinct molecular mechanisms influence sensitivity and resistance to MDM2 inhibitors in adult acute myelogenous leukemia. Blood 116, 71–80 (2010).

  108. 108.

    , , & Interactions between MDM2 and TP53 genetic alterations, and their impact on response to MDM2 inhibitors and other chemotherapeutic drugs in cancer cells. Clin. Cancer Res. 15, 7602–7607 (2009).

  109. 109.

    & MDM2 and prognosis. Mol. Cancer Res. 2, 1–8 (2004).

  110. 110.

    & Cyclotherapy: protection of normal cells and unshielding of cancer cells. Cell Cycle 1, 375–382 (2002).

  111. 111.

    et al. A panel of isogenic human cancer cells suggests a therapeutic approach for cancers with inactivated p53. Proc. Natl Acad. Sci. USA 106, 3964–3969 (2009).

  112. 112.

    , , & Specific activation of the p53 pathway by low dose actinomycin D: a new route to p53 based cyclotherapy. Cell Cycle 8, 2810–2818 (2009).

  113. 113.

    & One billion years of p53/p63/p73 evolution. Proc. Natl Acad. Sci. USA 106, 17609–17610 (2009).

  114. 114.

    , , & HDM2 antagonist Nutlin-3 disrupts p73-HDM2 binding and enhances p73 function. Oncogene 27, 997–1003 (2008).

  115. 115.

    et al. Mouse double minute antagonist Nutlin-3a enhances chemotherapy-induced apoptosis in cancer cells with mutant p53 by activating E2F1. Oncogene 26, 3473–3481 (2007).

  116. 116.

    , , , & Design of a novel MDM2 binding peptide based on the p53 family. Cell Cycle 8, 2828–2836 (2009).

  117. 117.

    & The MDM2 antagonist nutlin-3 sensitizes p53-null neuroblastoma cells to doxorubicin via E2F1 and TAp73. Int. J. Oncol. 34, 1395–1402 (2009).

  118. 118.

    , , , & E2F-1 transcriptional activity is a critical determinant of Mdm2 antagonist-induced apoptosis in human tumor cell lines. Oncogene 27, 5303–5314 (2008).

  119. 119.

    , , , & Mdm2-mediated NEDD8 modification of TAp73 regulates its transactivation function. J. Biol. Chem. 281, 34096–34103 (2006).

  120. 120.

    , & Degradation of p63 by Itch. Cell Cycle 5, 1735–1739 (2006).

  121. 121.

    et al. One, two, three—p53, p63, p73 and chemosensitivity. Drug Resist. Updat. 9, 288–306 (2006).

  122. 122.

    et al. Inhibition of p63 transcriptional activity by p14ARF: functional and physical link between human ARF tumor suppressor and a member of the p53 family. Mol. Cell Biol. 24, 8529–8540 (2004).

  123. 123.

    , & Small-molecule modulators of p53 family signaling and antitumor effects in p53-deficient human colon tumor xenografts. Proc. Natl Acad. Sci. USA 103, 11003–11008 (2006).

  124. 124.

    et al. Chemosensitivity linked to p73 function. Cancer Cell 3, 403–410 (2003).

  125. 125.

    et al. p53 polymorphism influences response in cancer chemotherapy via modulation of p73-dependent apoptosis. Cancer Cell 3, 387–402 (2003).

  126. 126.

    et al. Change of conformation of the DNA-binding domain of p53 is the only key element for binding of and interference with p73. J. Biol. Chem. 278, 10546–10555 (2003).

  127. 127.

    et al. Physical and functional interaction between p53 mutants and different isoforms of p73. J. Biol. Chem. 275, 29503–29512 (2000).

  128. 128.

    et al. Structural evolution of p53, p63, and p73: implication for heterotetramer formation. Proc. Natl Acad. Sci. USA 106, 17705–17710 (2009).

  129. 129.

    et al. Small-molecule RETRA suppresses mutant p53-bearing cancer cells through a p73-dependent salvage pathway. Proc. Natl Acad. Sci. USA 105, 6302–6307 (2008).

  130. 130.

    et al. p73 and p63 are homotetramers capable of weak heterotypic interactions with each other but not with p53. J. Biol. Chem. 274, 18709–18714 (1999).

  131. 131.

    et al. The biological, clinical and prognostic implications of p53 transcriptional pathways in breast cancers. J. Pathol. 220, 419–434 (2010).

  132. 132.

    et al. Mutant p53 drives invasion by promoting integrin recycling. Cell 139, 1327–1341 (2009).

  133. 133.

    et al. Activation of apoptosis in vivo by a hydrocarbon-stapled BH3 helix. Science 305, 1466–1470 (2004).

  134. 134.

    et al. Direct inhibition of the NOTCH transcription factor complex. Nature 462, 182–188 (2009).

  135. 135.

    et al. BAX activation is initiated at a novel interaction site. Nature 455, 1076–1081 (2008).

  136. 136.

    , , , & Reactivation of the p53 tumor suppressor pathway by a stapled p53 peptide. J. Am. Chem. Soc. 129, 2456–2457 (2007).

  137. 137.

    , & Stapled peptides in the p53 pathway: computer simulations reveal novel interactions of the staples with the target protein. Cell Cycle (in press).

  138. 138.

    , , & The MCL-1 BH3 helix is an exclusive MCL-1 inhibitor and apoptosis sensitizer. Nat. Chem. Biol. 6, 595–601 (2010).

  139. 139.

    , , , & MDMX overexpression prevents p53 activation by the MDM2 inhibitor Nutlin. J. Biol. Chem. 281, 33030–33035 (2006).

  140. 140.

    et al. Structure-based design of high affinity peptides inhibiting the interaction of p53 with MDM2 and MDMX. J. Biol. Chem. 285, 2174–2183 (2010).

  141. 141.

    et al. Identification and characterization of the first small molecule inhibitor of MDMX. J. Biol. Chem. 285, 10786–10796 (2010).

  142. 142.

    , & Structure of the human Mdmx protein bound to the p53 tumor suppressor transactivation domain. Cell Cycle 7, 2441–2443 (2008).

  143. 143.

    PyMOL molecular graphics system (DeLano Scientific, San Carlos, CA, USA).

  144. 144.

    et al. Structures of low molecular weight inhibitors bound to MDMX and MDM2 reveal new approaches for p53-MDMX/MDM2 antagonist drug discovery. Cell Cycle 9, 1104–1111 (2010).

  145. 145.

    et al. Systematic mutational analysis of peptide inhibition of the p53-MDM2/MDMX interactions. J. Mol. Biol. 398, 200–213 (2010).

Download references

Acknowledgements

C. F. Cheok and D. P. Lane are adjunct at the Department of Biochemistry, Yong Loo Lin School of Medicine (National University of Singapore); C. S. Verma is adjunct at the Department of Biological Sciences (National University of Singapore) and the School of Biological Sciences (Nanyang Technological University); J. Baselga is Director Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain. The authors thank T. L. Joseph for the models of MDM2 and MDM4.

Author information

Affiliations

  1. p53 Laboratory, A*STAR, 8A Biomedical Grove 06-06, Singapore 138648.

    • Chit Fang Cheok
    •  & David P. Lane
  2. Bioinformatics Institute, A*STAR, 30 Biopolis Street 07-01, Singapore 138671.

    • Chandra S. Verma
  3. Massachusetts General Hospital Cancer Center, Harvard Medical School, 55 Fruit Street, Lawrence House 108, Boston, MA 02114, USA.

    • José Baselga

Authors

  1. Search for Chit Fang Cheok in:

  2. Search for Chandra S. Verma in:

  3. Search for José Baselga in:

  4. Search for David P. Lane in:

Contributions

C. F. Cheok, C. S. Verma and D. P. Lane contributed to researching the data for the article discussions of the content, writing the article and to review and/or editing of the manuscript before submission. J. Baselga made a substantial contribution to the discussion of the content and the review and/or editing of the manuscript before submission.

Competing interests

The authors declare no competing financial interests.

Corresponding author

Correspondence to David P. Lane.

Supplementary information

Word documents

  1. 1.

    Supplementary Figure 1

    Toggling MDM2 activity: minimizing toxic effects associated with MDM2 inhibition.

About this article

Publication history

Published

DOI

https://doi.org/10.1038/nrclinonc.2010.174

Further reading